What Is GLP-1? 2026 Medical Expert Guide

Last reviewed: June 5, 2026

Last updated: June 5, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

Glucagon-like peptide-1 (GLP-1) medications have become the fastest-growing weight loss treatment class since their approval for diabetes in 1996. These compounds work by activating GLP-1 receptors in your brain and gut, reducing hunger signals and stabilizing blood sugar levels. PlexusDx medical experts explain how this hormone-mimicking technology can support sustainable weight management and metabolic health.

Understanding GLP-1: How This Natural Hormone Works

Glucagon-like peptide-1 is an incretin hormone your body produces naturally in response to eating. When you consume food, intestinal cells release GLP-1 into your bloodstream, where it signals your pancreas to release insulin and tells your brain that you feel full. This cascade of effects helps regulate blood sugar after meals and limits how much you eat before feeling satisfied. GLP-1 receptor agonist medications recreate this natural signal, allowing your body to experience these satiety and metabolic benefits even before food enters your system.

The GLP-1 receptor appears in multiple tissues throughout your body, including your brain's appetite control center, your stomach, and your pancreas. When a GLP-1 medication binds to these receptors, it slows how quickly your stomach empties food into your intestines—a process called gastric emptying. This prolonged fullness sensation, combined with reduced appetite signals to your brain, creates a powerful mechanism for weight loss without requiring extreme calorie restriction. Research published in 2024–2025 demonstrates that GLP-1 agonists reduce body weight by 15–22% over one year when combined with lifestyle changes.

GLP-1 Medications Available in 2026: Semaglutide vs. Tirzepatide

Semaglutide is a GLP-1 receptor agonist that activates GLP-1 signaling pathways to lower appetite and improve blood sugar control. PlexusDx offers compounded semaglutide injections starting at $149 per month, sourced from licensed 503A compounding pharmacies and available across all 50 states without insurance requirements. Semaglutide typically reaches peak effect within 4–7 weeks at a stable dose, making it a predictable option for patients seeking gradual, manageable weight loss. Clinical trials show semaglutide users experience an average weight loss of 10–15% of body weight over 68 weeks.

Tirzepatide is a dual GLP-1 and GIP receptor agonist, meaning it activates two appetite-control pathways instead of one. This dual mechanism often produces more dramatic weight loss than semaglutide alone—clinical data from 2023–2024 trials showed tirzepatide users lost 20–22% of body weight over 72 weeks. PlexusDx compounded tirzepatide injections start at $249 per month, and oral tirzepatide is available at $279 per month. For patients seeking maximum effect from a single compound, tirzepatide represents a more potent option, though individual response varies based on genetics and lifestyle factors.

Genetic Testing for Personalized GLP-1 Therapy

Not every patient responds identically to GLP-1 therapy because genetic variations influence how your body processes these medications and responds to appetite signals. PlexusDx offers the Precision Peptide Genetic Test for $99 as an add-on after your first month of treatment. This peptide-pathway genetic test analyzes key variants including GLP1R rs6923761, GIPR rs1800437, FTO rs9939609, and MC4R rs17782313—genes that directly influence GLP-1 receptor sensitivity, GIP signaling, fat metabolism, and appetite regulation. By mapping your unique genetic profile across 14 metabolic pathways and 49 peptides, PlexusDx clinicians can identify which medication and dose strategy will produce the best results for your body.

Genetic insights allow your PlexusDx care team to recommend whether semaglutide, tirzepatide, the Microdose GLP-1 Protocol ($129/mo), or GLP-Squared dual-compound injections ($249/mo) align with your metabolic profile. Patients with certain GLP1R variants may experience stronger satiety signals, while those with specific FTO or MC4R variations may benefit from tirzepatide's dual-pathway approach. This precision medicine strategy reduces trial-and-error adjustments and accelerates your path to an effective, sustainable treatment plan tailored to your genetic predispositions.

PlexusDx GLP-1 Treatment Options and Cost Structure

PlexusDx offers multiple GLP-1 formulations to match different patient preferences and clinical goals. Compounded semaglutide injections begin at $149 per month and are available from licensed 503A compounding pharmacies across all states. Oral semaglutide ($249/mo) provides an injection-free alternative, though injection forms typically achieve faster, more consistent absorption. The innovative Microdose GLP-1 Protocol ($129/mo flat) serves patients who prefer minimal doses or are highly sensitive to GLP-1 effects, while GLP-Squared injection ($249/mo) combines semaglutide and tirzepatide into a single compound for additive appetite-suppression pathways.

All PlexusDx medications are priced on a flat monthly basis—your dose may increase as your treatment progresses, but your monthly price remains stable across all commitment tiers. No insurance is required, no membership fees apply, and both HSA and FSA accounts cover compounded GLP-1 medications. This transparent, accessible pricing model removes financial barriers that historically prevented patients from accessing prescription-strength weight loss therapy. PlexusDx serves all 50 states and combines licensed compounding with telehealth consultations, making personalized GLP-1 treatment available regardless of your location or insurance status.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

How quickly will I see weight loss results with GLP-1 therapy?

Most PlexusDx patients experience noticeable appetite reduction within 2–4 weeks of starting treatment, with measurable weight loss appearing by week 4–8. Full results typically emerge over 12–16 weeks as your dose stabilizes and your body adapts to the medication.

What is the difference between GLP-1 and tirzepatide?

GLP-1 medications like semaglutide activate one appetite-control receptor, while tirzepatide activates both GLP-1 and GIP receptors simultaneously. This dual pathway gives tirzepatide a more powerful effect on appetite suppression and weight loss in clinical trials.

Do I need insurance to access PlexusDx GLP-1 medications?

No. PlexusDx serves all 50 states without requiring insurance, membership fees, or prior authorization delays. Compounded semaglutide begins at $149/mo and tirzepatide at $249/mo, with both HSA and FSA accounts eligible for reimbursement. This direct-access model makes prescription-strength GLP-1 therapy affordable and immediately available.

Are compounded GLP-1 medications safe?

Yes. PlexusDx sources all compounded medications from licensed 503A compounding pharmacies that meet strict FDA and state pharmacy board standards for sterility, potency, and quality. While compounded medications are not FDA-approved, they are legally prescribed and commonly used when brand-name formulations are unavailable or unaffordable.

How does the Precision Peptide Genetic Test help my treatment?

The Precision Peptide Genetic Test ($99 add-on) analyzes key variants in GLP1R, GIPR, FTO, and MC4R genes that influence your appetite regulation and medication response. PlexusDx clinicians use these results to predict whether semaglutide, tirzepatide, or dual-compound therapy will work best for your genetic profile.

What is GLP-1? A 2026 Breakdown from Our Medical Experts